Welcome to our dedicated page for Naturl Alt Intl news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Naturl Alt Intl stock.
Naturl Alt Intl (NAII) delivers science-backed nutritional solutions through advanced manufacturing and strategic partnerships. This news hub provides investors and industry professionals with essential updates on the company's operational milestones, product innovations, and market positioning.
Access authoritative reporting on NAII's financial disclosures, regulatory achievements, and clinical research collaborations. Our curated collection includes earnings reports, manufacturing capacity expansions, patent filings, and quality assurance certifications - all critical for evaluating the company's industry leadership.
Key updates cover formulation advancements, production facility upgrades, and partnership agreements with healthcare organizations. Track NAII's progress in developing condition-specific supplements while maintaining compliance with global regulatory standards.
Bookmark this page for streamlined access to NAII's latest developments in private-label manufacturing and nutritional science. Check regularly for verified updates that matter to stakeholders in the nutraceuticals sector.
Natural Alternatives International, Inc. (NAII) has authorized a $1.0 million increase in its stock repurchase plan, raising the total to $19.0 million. This allows for continued buybacks based on market conditions. NAII has already repurchased 2.1 million shares and has $1.2 million remaining for future purchases. CEO Mark A. Le Doux expressed confidence in the company's value and growth, highlighting the upcoming operational launch of their new facility in Carlsbad, CA.
Natural Alternatives International (NAII) reported a net income of $1.1 million for Q1 FY 2023, down from $3.3 million in Q1 FY 2022. Net sales increased by 12.5% to $43.1 million compared to $38.3 million last year, driven mainly by a 24.4% rise in private-label contract manufacturing. However, CarnoSyn® beta-alanine revenues dropped 71.5% to $1.4 million, impacted by inflation and a slowdown in the Sports Nutrition sector. Although NAII anticipates slight sales growth for FY 2023, operating income may suffer due to rising costs and unfavorable currency effects.
Natural Alternatives International, Inc. (NAII) reported a strong performance in Q4 2022, achieving $52.5 million in net sales, up 18.3% year-over-year. Net income rose to $3.1 million or $0.52 per diluted share, compared to $3.0 million and $0.47 in Q4 2021. However, overall annual sales decreased 4.2% to $171 million. The company anticipates 10%-15% net sales growth for fiscal 2023, but warns of potential operating income impacts due to inflation and rising operational costs. They also outlined ongoing challenges in their supply chain and have begun constructing a new manufacturing facility.
Natural Alternatives International (NAII) reported a 30.7% increase in net income for Q3 FY2022, totaling $2.5 million or $0.41 per diluted share. Net sales, however, fell 8.5% to $42.4 million, driven by a 10.8% drop in private-label contract manufacturing sales due to a 40% reduction in sales from its largest customer. Despite ongoing supply chain issues, NAII anticipates 18%-21% growth in net sales for Q4 FY2022. The company holds $18.6 million in cash and a working capital of $53.8 million, showcasing resilience amid challenges.
Natural Alternatives International, Inc. (NAII), a leader in custom nutritional supplement manufacturing, has appointed Aaron Starr as the new Vice President of CarnoSyn Brands. In this role, Starr will oversee operational performance, manage P&L, and implement strategic planning and marketing initiatives aimed at enhancing customer relationships. He brings extensive experience from his previous positions at NAI and holds an MBA in Financial Management. This leadership change aims to bolster sales and expand opportunities in the sports nutrition and health sectors.
Natural Alternatives International (NAII) reported a net income of $1.8 million, or $0.30 per diluted share, on net sales of $37.7 million for Q2 fiscal 2022, down from $3.6 million and $48.1 million in Q2 fiscal 2021. Private-label contract manufacturing sales fell by 25.7% to $33.7 million, mainly due to a 48% drop from their largest customer, compounded by supply chain issues. Conversely, CarnoSyn® sales rose by 46.9% to $4.1 million. For the first half of fiscal 2022, net income was $5.1 million, down from $5.9 million. Looking ahead, NAII anticipates slight growth in net sales for fiscal 2022.
Natural Alternatives International, Inc. (NAII) announces the appointment of Sherri Balzer as Business Development Manager for CarnoSyn Brands. With over 25 years in the health and wellness sector, Balzer aims to enhance growth through strategic client management and partnerships. Her experience includes senior roles at Kb Pure Essentials and Cultivate. Balzer emphasizes her commitment to improving consumer health and plans to focus on SR CarnoSyn, which offers clinically proven benefits. This addition is expected to boost revenue and market share for NAII in the health and wellness industry.
Natural Alternatives International, Inc. (NAII) announced a $3.0 million increase in its stock repurchase plan, raising the total authorized amount to $18.0 million. The company has already repurchased 1.9 million shares at an average price of less than $8 per share since the plan's inception. NAII's CEO believes the stock is undervalued and expresses confidence in the company's growth potential, particularly with a new manufacturing facility expected to be operational by Fall 2022.
Natural Alternatives International, Inc. (NAII) reported a net income of $3.3 million or $0.51 per diluted share for Q1 FY2022, a rise from $2.3 million or $0.35 per share in the previous year. Net sales declined by 3.5% to $38.3 million, influenced by a 45% drop in sales to its largest customer due to European market issues. However, CarnoSyn® sales surged by 77.1% to $4.7 million. Looking forward, NAII anticipates a 7-10% increase in FY2022 net sales despite first-half declines due to supply chain constraints.
Natural Alternatives International, Inc. (NAI) will release its first quarter 2022 financial results on November 9, 2021, after market close. The company's operations include the formulation and marketing of customized nutritional supplements and strategic partnerships. A comprehensive investor presentation will be available following the earnings release. The press release includes forward-looking statements and cautions about potential risks and uncertainties affecting future financial performance. Further details can be found on NAI's website.
